Physician
Obstetrics & Gynecology
Dr. Karl C. Podratz, MD
|
|
Give Review
Karl Podratz is an expert in the field of Obstetrics & Gynecology. He went to medical school at Saint Louis University School of Medicine. Saint Louis University School of Medicine is ranked 67/57 in Research/PrimaryCare. He has 2 awards "Fellow (FACS)" and "Whos Who in Medicine and Healthcare". Karl Podratz is also a published doctor. He has 96 paper published. The most recent paper is: The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.
Publications
- The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.
- Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
- Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.
- Discovery and validation of methylation markers for endometrial cancer.
- Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: A histologic dichotomy.
- Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer.
- Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer.
- Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.
- Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.
- Hypomethylation and Activation of Syncytin-1 in Endometriotic Tissue.
- Development of an intracellular, DNA Methyltransferase-Specific, and Gene-Specific Assay for Studying Dynamic DNA Methylation.
- Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
- Bone metastases in endometrial cancer: Report on 19 patients and review of the medical literature.
- Predictors and costs of surgical site infections in patients with endometrial cancer.
- HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines.
- Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma.
- Factors predictive of postoperative morbidity and cost in patients with endometrial cancer.
- Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer.
- Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer.
- Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma.
- Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature.
- The impact of surgical guidelines and periodic quality assessment on the staging of endometrial cancer.
- Risk Factors for Developing Multiple Malignancies in Patients With Endometrial Cancer.
- Expression and functional significance of HtrA1 loss in endometrial cancer.
- Resection of the inferior vena cava for an isolated para-aortic recurrence of endometrial cancer: report of a case.
- The impact of multi-modal therapy on survival for uterine carcinosarcomas.
- Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
- Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy.
- Re: Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
- Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience.
- Endometrial stromal sarcoma: treatment and patterns of recurrence.
- Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
- Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
- Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer.
- Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer.
- Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas.
- Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.
- Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
- Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.
- Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.
- Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
- Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
- Treatment of pulmonary recurrences in patients with endometrial cancer.
- A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.
- Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment.
- Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva.
- Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.
- Clinical and pathologic correlates in surgical stage II endometrial carcinoma.
- Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.
- Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
- Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
- Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.
- Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
- hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications.
- Quality improvement in gynecologic surgery: the new frontier.
- Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer.
- Splenectomy as part of cytoreductive surgery in ovarian cancer.
- Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes.
- Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients.
- The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.
- Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent met...
- Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.
- Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
- Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon.
- Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
- Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
- Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.
- Predictors of vaginal relapse in stage I endometrial cancer.
- Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva.
- Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial ...
- Endometrial cancer: can nodal status be predicted with curettage?
- Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
- Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer.
- Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer.
- Up-regulation of DNA methyltransferase 3B expression in endometrial cancers.
- Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
- High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy.
- Diaphragm resection for ovarian cancer: technique and short-term complications.
- Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
- Endometrial carcinoma: paraaortic dissemination.
- Characteristics of patients with vaginal rupture and evisceration.
- Uterine papillary serous carcinomas: the exigency for clinical trials.
- Long-term follow-up of women with ovarian cancer after positive second-look laparotomy.
- Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva.
- Endometrial cancer: predictors of peritoneal failure.
- Hepatic resection for metachronous metastases from ovarian carcinoma.
- Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
- Surgical stage I endometrial cancer: predictors of distant failure and death.
- Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisp...
- Stage IIIC endometrioid corpus cancer includes distinct subgroups.
- Assessment of prognostic factors in stage IIIA endometrial cancer.
- Prevention and management of acute intraoperative bleeding.
- Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.
- Predictors of lymphatic failure in endometrial cancer.
- HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.
Schools
Saint Louis University School Of Medicine
University Chicago Hosps
Mayo Clinic Rochester
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- Fellow (FACS)
- Whos Who in Medicine and Healthcare
Education
-
Mayo School of Graduate Medical Education -
University of Chicago -
Saint Louis University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Similar Doctors
|
|
Dr. Jamie N. Bakkum-Gamez, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John B. Gebhart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emanuel C. Trabuco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roger D. Kempers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William A. Cliby, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Monica B. Jones, MD |
|
|
Dr. Elizabeth A. Baldwin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle L. Delplanche, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew R. Hopkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eleftheria Kalogera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erik D. Hokenstad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy O. Wilson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexis N. Hokenstad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Abraham Peedicayil, MB BS |